Why Are Investors Piling Into These Four Stocks?

Shares of Lipocine Inc (NASDAQ:LPCN) are up by over 27% on strong volume after the FDA assigned a PDUFA (Prescription Drug User Fee Act) date of June 28, 2016 for the company’s leading drug candidate LPCN 1021, a potential oral testosterone product for testosterone replacement therapy in adult males for conditions associated with an absence or deficiency of endogenous testosterone (‘hypogonadism’). The FDA communication letter did not mention any need of an advisory committee for advice on the NDA for LPCN 1021, which can be construed as an optimistic sign. Given an average of half a million prescriptions are dispensed for TRT a month and many of the topical products for TRT have black box warnings, some investors are bullish on the company. According to our database, 12 funds owned $47.9 million of Lipocine Inc (NASDAQ:LPCN)’s shares on June 30, accounting for 30.70% of the float.

Last but not least, Syngenta AG (ADR) (NYSE:SYT) shares are up 6% after Bloomberg published a report stating ChemChina is interested in buying the company. According to the article, ChemChina made an offer of around 449 Swiss francs per share, valuing the company at around $42 billion. Syngenta turned down the offer, however, as management thinks the offer is too low given the regulatory risks. Although a deal between the two companies isn’t imminent, the two are still talking and a deal could potentially be made within several weeks. Syngenta is also considering other M&A options as well, including talking to other potential acquirers.

Disclosure:None